Hepatitis C Virus

France-based biopharm company awarded grant for hepatitis C therapeutic vaccine program

Published in Hepatitis Weekly, February 20th, 2006

Transgene S.A. announced that it has been awarded funding by the Lyon Biopole Competitiveness Cluster (Pole de competitivite) for the development of its therapeutic vaccine candidate against hepatitis C chronic infection (HCV).

This funding is expected to total EUR 1.3 million (US$1.56 million) over the next 3 years and will cover 30% of the research and development costs for this program.

The grant aims at strengthening the development of Transgene's vaccine candidate TG4040 (MVA-HCV), which is undergoing preclinical studies and should enter phase 1/2 trial by mid-2006 to treat patients non responding to standard therapy. The TG4040 development...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-02-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry